ZORVOLEX Drug Patent Profile

Which patents cover Zorvolex, and when can generic versions of Zorvolex launch?

Zorvolex is a drug marketed by Zyla and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in ZORVOLEX is diclofenac. There is one drug master file entry for this compound. Additional details are available on the diclofenac profile page.

DrugPatentWatch^® Generic Entry Outlook for Zorvolex

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 23, 2030. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are four tentative approvals for the generic drug (diclofenac), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for ZORVOLEX

US Patents:	7
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	99
Clinical Trials:	2
Patent Applications:	4,481
Drug Prices:	Drug price information for ZORVOLEX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZORVOLEX
What excipients (inactive ingredients) are in ZORVOLEX?	ZORVOLEX excipients list
DailyMed Link:	ZORVOLEX at DailyMed

See drug prices for ZORVOLEX

See drug sales revenues for ZORVOLEX

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZORVOLEX

Constraining patent/regulatory exclusivity:

9,186,328

NDA:

204592

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZORVOLEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Regeneron Pharmaceuticals	Phase 2
Teva Pharmaceutical Industries, Ltd.	Phase 2
Regeneron Pharmaceuticals	Phase 3

See all ZORVOLEX clinical trials

Paragraph IV (Patent) Challenges for ZORVOLEX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZORVOLEX	Capsules	diclofenac	18 mg and 35 mg	204592	1	2014-06-06

US Patents and Regulatory Information for ZORVOLEX

ZORVOLEX is protected by seven US patents.

This potential generic entry date is based on patent 9,186,328.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zyla	ZORVOLEX	diclofenac	CAPSULE;ORAL	204592-001	Oct 18, 2013		DISCN	Yes	No	9,186,328
Zyla	ZORVOLEX	diclofenac	CAPSULE;ORAL	204592-001	Oct 18, 2013		DISCN	Yes	No	8,679,544		Y
Zyla	ZORVOLEX	diclofenac	CAPSULE;ORAL	204592-001	Oct 18, 2013		DISCN	Yes	No	9,180,096		Y
Zyla	ZORVOLEX	diclofenac	CAPSULE;ORAL	204592-002	Oct 18, 2013		DISCN	Yes	No	9,180,096		Y
Zyla	ZORVOLEX	diclofenac	CAPSULE;ORAL	204592-002	Oct 18, 2013		DISCN	Yes	No	9,180,095
Zyla	ZORVOLEX	diclofenac	CAPSULE;ORAL	204592-002	Oct 18, 2013		DISCN	Yes	No	9,017,721		Y

International Patents for ZORVOLEX

When does loss-of-exclusivity occur for ZORVOLEX?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Australia

Brazil

Canada

China

Colombia

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Malaysia

Mexico

Morocco

New Zealand

Philippines

Singapore

South Africa

South Korea

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZORVOLEX around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	3774
Australia	2010239080
Australia	2014208310
Brazil	PI1014272
Canada	2759123
China	102438610

Zorvolex Market Dynamics, Financial Trajectory, Patents, and Generic Competition

Last updated: August 17, 2026

Zorvolex is a branded, low-dose diclofenac product marketed for acute pain and osteoarthritis pain. Its commercial proposition is based on SoluMatrix fine-particle technology, which enables 18 mg and 35 mg capsules rather than conventional 50 mg diclofenac dosing. The product faces intense competition from low-cost generic diclofenac and other NSAIDs, while its formulation patents and branded reimbursement position provide the main barriers to substitution.

Zorvolex does not have biologic exclusivity or biosimilar exposure. Its principal risks are generic substitution, payer restrictions, patent challenges, declining branded NSAID demand, and limited product-level financial disclosure.

What is Zorvolex and who markets it?

Zorvolex contains diclofenac, a nonsteroidal anti-inflammatory drug. The FDA approved Zorvolex capsules in October 2013 for mild-to-moderate acute pain and later for osteoarthritis pain. The product is available in 18 mg and 35 mg strengths. The recommended osteoarthritis regimen is 35 mg three times daily, while acute-pain dosing depends on the approved indication and prescribing information.[1]

The product originated with Iroko Pharmaceuticals, which developed the SoluMatrix platform. Commercial rights subsequently moved through Zyla Life Sciences and Assertio. Assertio’s current portfolio includes several branded specialty products, but it has not generally reported Zorvolex revenue as a separate public reporting segment.[2]

Zorvolex product profile

Attribute	Zorvolex
Active ingredient	Diclofenac
Drug class	NSAID
Dosage form	Oral capsule
Strengths	18 mg and 35 mg
Initial FDA approval	2013
Primary uses	Acute pain and osteoarthritis pain
Developer	Iroko Pharmaceuticals
Technology	SoluMatrix fine-particle technology
Current commercial context	Branded specialty pharmaceutical
Biosimilar risk	None
Main substitution risk	Generic diclofenac and competing NSAIDs

Zorvolex’s formulation uses smaller diclofenac particles to support a lower milligram dose. The product is not a new active ingredient. Its commercial value therefore depends on formulation differentiation, physician familiarity, reimbursement, and the ability to maintain a price premium over generic diclofenac.

What patents protect Zorvolex?

Zorvolex’s patent protection is directed primarily to the formulation, particle-size characteristics, dosage form, and related methods of use rather than to diclofenac itself. Diclofenac is an old active ingredient with extensive generic availability.

The FDA Orange Book is the principal source for identifying patents listed against approved Zorvolex strengths. Listed patents can include formulation and method-of-use claims, but Orange Book presence does not guarantee that every claim will survive litigation or post-grant review.[3]

What formulations are protected by Zorvolex patents?

The relevant intellectual-property strategy centers on:

• Fine-particle diclofenac formulations.
• Low-dose oral capsules.
• Pharmaceutical compositions with specified particle-size or dissolution characteristics.
• Methods for treating acute pain or osteoarthritis using the formulation.
• Manufacturing processes that produce the desired particle distribution and bioavailability profile.

This structure gives the owner more protection than a simple compound patent would provide for an old NSAID. It also leaves the estate vulnerable to design-around strategies involving particle size, excipients, capsule composition, dissolution behavior, or dosage instructions.

How strong is the Zorvolex patent estate?

The estate is commercially meaningful but narrower than the estate for a new chemical entity. Its strength depends on the breadth of the formulation claims, the quality of laboratory and clinical evidence supporting the claims, and whether an ANDA applicant can demonstrate non-infringement or invalidity.

The main limitations are:

1. Diclofenac is widely available in competing oral, topical, injectable, and liquid formulations.
2. A generic applicant can challenge formulation claims without challenging the underlying active ingredient.
3. Formulation patents often face obviousness arguments based on known micronization, particle-size control, and NSAID delivery techniques.
4. Method-of-use claims can be difficult to enforce when the underlying indication is already established for diclofenac.
5. Patent expiry alone does not determine commercial exclusivity if listed patents are invalidated or carved out through a Paragraph IV process.

When did Zorvolex lose exclusivity?

Zorvolex’s regulatory exclusivity and patent exclusivity are separate concepts. The product was approved in 2013, but approval did not create long-term new-chemical-entity exclusivity because diclofenac was already an established active ingredient.

Any three-year exclusivity associated with approval of a new clinical investigation would have expired years ago. The relevant continuing protection has therefore been patent-based and commercial rather than NCE-based.[1][4]

Zorvolex exclusivity timeline

Period	Event	Commercial effect
2013	FDA approval of Zorvolex	Established branded product
2013 onward	Formulation and method-of-use patent protection	Delayed or complicated generic entry
2016-2019	Expansion of branded NSAID portfolios and ownership changes	Increased commercial competition
2020 onward	Assertio/Zyla portfolio integration	Product managed within a broader specialty portfolio
Current period	Generic diclofenac remains widely available	Persistent pricing and substitution pressure

There is no single “Zorvolex patent expiration date” that captures the entire estate. Different patents may expire at different times, and pediatric extensions, terminal disclaimers, patent-term adjustments, litigation outcomes, and Orange Book delistings can affect the effective barrier.

What is the Orange Book status of Zorvolex?

Zorvolex is an FDA-approved prescription drug listed in the Orange Book. The Orange Book identifies the approved drug product, dosage forms, strengths, therapeutic-equivalence information, and any patents submitted by the innovator for listing.[3]

The Orange Book status matters because an ANDA applicant must address listed patents through one of four certifications:

• Paragraph I: no patent information is listed.
• Paragraph II: the listed patent has expired.
• Paragraph III: the applicant will wait until patent expiration.
• Paragraph IV: the patent is invalid, unenforceable, or will not be infringed.

A Paragraph IV filing can trigger patent litigation and a potential 30-month FDA approval stay under the Hatch-Waxman Act. The commercial outcome depends on whether the brand owner sues, whether the generic prevails, and whether the parties settle.

What Paragraph IV challenges affect Zorvolex?

Zorvolex has been exposed to the standard ANDA challenge risk associated with branded formulation products. Generic applicants can target the capsule formulation, particle-size specifications, dissolution profile, or method-of-use patents while accepting the diclofenac active ingredient.

Public company disclosures have not consistently provided a single consolidated, current list of all ANDA applicants, Paragraph IV notices, litigation outcomes, and settlement terms for every Zorvolex strength. The practical risk assessment is therefore based on the product’s formulation-patent structure and the availability of generic diclofenac alternatives.

A successful Paragraph IV challenge could produce an accelerated generic launch before the latest asserted patent expiration. A non-infringement settlement could permit entry on a negotiated date, often with limited disclosure of commercial terms.

Which companies compete with Zorvolex?

Zorvolex competes across several NSAID categories rather than against one direct product.

Direct and indirect competitors

Competitor	Active ingredient	Form	Competitive relevance
Generic diclofenac sodium	Diclofenac	Tablets, topical products, other forms	Lowest-cost direct alternative
Voltaren products	Diclofenac	Topical and oral legacy products	Strong brand recognition
Cambia	Diclofenac potassium	Oral powder for migraine	Competes for diclofenac prescribing
Tivorbex	Indomethacin	Capsules	Branded NSAID alternative
Celebrex and generic celecoxib	Celecoxib	Capsules	COX-2 alternative
Meloxicam	Meloxicam	Tablets and other forms	Broad generic NSAID competition
Naproxen	Naproxen	Tablets and suspensions	Low-cost first-line alternative
Ibuprofen	Ibuprofen	Tablets and liquids	High-volume OTC and prescription competitor
Pennsaid	Diclofenac sodium	Topical solution	Alternative route of administration

Zorvolex’s direct competitive weakness is its price differential versus generic diclofenac. Its advantages are dose design, branded support, and a formulation positioned for lower-dose diclofenac delivery. Those advantages are most valuable in patients whose prescribers believe the product’s formulation or dosing profile justifies higher cost.

What are the market dynamics for Zorvolex?

Zorvolex operates in a mature NSAID market with high clinical substitutability. Generic entry has reduced prices for conventional diclofenac, ibuprofen, naproxen, meloxicam, and celecoxib. Payers generally favor generic NSAIDs before branded formulations.

The product’s market dynamics are driven by five factors:

1. Formulary placement and prior authorization.
2. Physician willingness to prescribe branded diclofenac.
3. Patient copay support and affordability programs.
4. Evidence supporting the formulation’s dosing or tolerability profile.
5. The timing and scope of generic capsule competition.

Zorvolex also carries the class-wide NSAID risks identified in its FDA labeling, including cardiovascular thrombotic events, gastrointestinal bleeding, renal toxicity, hypertension, and serious hypersensitivity reactions.[1] These risks limit the extent to which a lower-dose formulation can create a broad clinical premium.

Does Zorvolex have a meaningful clinical differentiation?

The product has formulation differentiation, but its clinical differentiation is more limited. Zorvolex uses a lower milligram dose than conventional immediate-release diclofenac products, yet the active ingredient remains diclofenac and the safety warnings remain materially aligned with the NSAID class.

The commercial question is not whether Zorvolex is different from diclofenac at a formulation level. It is whether the difference produces enough clinical or operational value to justify branded pricing after accounting for payer controls.

What is Zorvolex’s financial trajectory?

Zorvolex revenue is difficult to isolate because the commercial owners have generally reported product portfolios rather than a standalone Zorvolex income statement. Assertio’s filings discuss product sales, royalties, license arrangements, and portfolio concentration, but public reporting does not consistently provide a complete annual revenue series for Zorvolex alone.[2]

The financial trajectory is best characterized as mature branded-product revenue under pressure rather than a growth-stage asset.

Financial drivers

Driver	Effect on Zorvolex
Generic diclofenac pricing	Compresses the ceiling for branded pricing
Payer utilization controls	Reduces prescription conversion
Patient assistance	Supports volume but can reduce net price
Formulation patents	Delay or complicate direct generic entry
Portfolio ownership changes	Affect promotion, accounting, and reported sales
NSAID class safety	Limits premium positioning
Specialty-pharma sales infrastructure	Adds fixed commercial cost

A successful generic launch would likely cause a rapid reduction in branded volume and net price. The decline could be slower if the generic is limited to one strength, lacks an AB-rated equivalent, or encounters manufacturing constraints. It could be faster if multiple generic manufacturers launch simultaneously.

Product-level revenue exposure is strategically important even if Zorvolex is not a major share of total Assertio revenue. For a specialty company with a concentrated portfolio, a mature branded product can still contribute cash flow, sales-force leverage, and payer relationships. Its value is lower when the product requires continued promotional spending without sustained pricing power.

What generic entry risks exist for Zorvolex?

The highest-risk scenario is multi-manufacturer generic entry into both 18 mg and 35 mg capsules. That outcome would remove much of the product’s pricing advantage and could shift prescriptions to generic diclofenac or other low-cost NSAIDs.

Generic launch scenarios

Scenario	Likely effect
No approved generic	Branded sales continue, subject to payer pressure
Single generic launch	Moderate price and volume erosion
Multiple generic launches	Rapid price compression and share loss
At-risk Paragraph IV launch	Potential abrupt erosion followed by litigation damages
Authorized generic	Brand owner retains part of the generic economics
Narrow label carve-out	Partial substitution, with continued branded use in protected indications

The economic impact depends on whether the generic is therapeutically equivalent and whether pharmacies can substitute automatically. A generic that receives an AB rating against the relevant Zorvolex reference product would present greater commercial risk than a product requiring a new prescription.

Is Zorvolex exposed to biosimilar competition?

No. Zorvolex is a small-molecule diclofenac capsule, not a biologic. Biosimilar approval pathways under the Public Health Service Act do not apply. Competition proceeds through the ANDA pathway under the Federal Food, Drug, and Cosmetic Act.

The relevant regulatory risks are:

• ANDA approval.
• Paragraph IV patent litigation.
• Therapeutic-equivalence ratings.
• Label carve-outs.
• Manufacturing and supply continuity.
• State substitution rules.

What patent litigation affects Zorvolex?

Zorvolex litigation risk is centered on ANDA applicants challenging formulation or method-of-use patents. The most consequential litigation questions are whether the generic product meets the asserted claim limitations and whether the patents are valid and enforceable.

Potential litigation outcomes include:

1. Brand victory with delayed generic approval.
2. Generic victory with approval before the expected patent date.
3. Settlement with a future generic-entry date.
4. Narrowed claims after claim construction or summary judgment.
5. Launch of a non-infringing product with a modified formulation.
6. Commercial launch followed by damages litigation.

Settlement agreements can materially change the effective exclusivity date, but their value depends on the number of generic parties, entry restrictions, authorized-generic provisions, and whether the settlement includes licenses to additional patents.

How does Zorvolex compare with other branded NSAIDs?

Zorvolex has a weaker active-ingredient moat than products protected by a novel molecule, but it may have more formulation differentiation than conventional generic diclofenac. Its commercial position is also less durable than that of a product with a large indication-specific market.

Factor	Zorvolex	Generic diclofenac	Celecoxib	Topical diclofenac
Active-ingredient protection	None	None	None for generic versions	None
Formulation differentiation	Moderate	Low	Product-dependent	Route-specific
Brand pricing power	Limited to moderate	Low	Moderate for branded products	Variable
Generic substitution	High risk	Established	High for generic celecoxib	Established
Biosimilar risk	None	None	None	None
Main commercial advantage	Low-dose formulation	Price	COX-2 positioning	Local administration

What are Zorvolex’s geographic and manufacturing barriers?

Zorvolex’s commercial protection is primarily U.S.-focused because the FDA Orange Book and Hatch-Waxman framework govern U.S. generic entry. International protection depends on country-specific patent filings, regulatory approvals, and local diclofenac competition.

Manufacturing barriers may include:

• Fine-particle production capabilities.
• Consistent particle-size distribution.
• Dissolution and content-uniformity control.
• Scale-up of the SoluMatrix process.
• Qualification of specialized suppliers.
• Reproduction of the reference product’s performance characteristics.

These barriers can delay generic approval even when patent risk is manageable. They are less durable than a strong composition-of-matter patent because established contract manufacturers and formulation specialists may eventually reproduce the required product attributes.

Key Takeaways

• Zorvolex is a branded diclofenac capsule approved in 2013 for acute pain and osteoarthritis pain.
• Its differentiation comes from SoluMatrix fine-particle technology and 18 mg and 35 mg low-dose capsules.
• Diclofenac itself is off-patent, so Zorvolex depends on formulation and method-of-use protection.
• The product has no biosimilar risk. Its principal threat is ANDA-based generic competition.
• Public filings do not consistently disclose a complete standalone Zorvolex revenue history.
• The product’s financial profile is mature and exposed to payer restrictions, generic substitution, and branded NSAID price compression.
• A successful Paragraph IV challenge or multi-manufacturer generic launch would likely produce rapid volume and net-price erosion.
• Manufacturing complexity may delay competition but is unlikely to create a permanent barrier.
• Zorvolex’s long-term value depends on the enforceability of its remaining formulation claims and the owner’s ability to maintain reimbursement and prescribing support.

FAQs

Does Zorvolex have a different active ingredient from generic diclofenac?

No. Zorvolex contains diclofenac. Its differentiation is based on formulation, particle engineering, dosage strength, and delivery characteristics.

Can pharmacies automatically substitute generic diclofenac for Zorvolex?

Automatic substitution depends on FDA therapeutic-equivalence ratings, state law, and the specific generic product. A generic product must be approved and rated appropriately before pharmacy-level substitution can occur.

Is Zorvolex more protected than ordinary generic diclofenac?

Yes, at the formulation level. Zorvolex may have formulation and method-of-use patents, while conventional generic diclofenac generally competes without those branded-product constraints. The protection is narrower than a new-molecule patent estate.

Does Zorvolex qualify for a biologic patent or biosimilar pathway?

No. Zorvolex is a small-molecule drug regulated through the conventional NDA and ANDA framework.

What would most increase Zorvolex’s commercial value?

The strongest value drivers would be enforceable remaining formulation claims, delayed or limited generic entry, improved formulary access, evidence supporting a meaningful clinical benefit, and stable manufacturing supply.

References

1. U.S. Food and Drug Administration. (2024). Zorvolex prescribing information.
2. Assertio Holdings, Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Guidance for industry: Applications covered by Section 505(b)(2).